ICI combination therapy (ipilimumab + nivolumab) [66], as well as combined immune-checkpoint blockade with BRAF and MEK-inhibition in BRAF mutant melanoma (atezolizumab + vemurafenib + cobimetinib) [68], represent therapeutic options in selected cases according to the current National Comprehensive Cancer Network (NCCN) treatment guidelines [69]; however, the latter combinations have not yet demonstrated an OS benefit. The gene discussed is BRAF; the disease is melanoma.